Amgen and Humana Inc. will collaborate on finding opportunities to improve health outcomes by analyzing the real-world health care experiences of Humana's 13 million members.
"The rising cost of disease is challenging the sustainability of our health care system in the U.S., and is motivating innovators to urgently develop new therapeutic options and partner on opportunities to improve the quality and efficiency of care and reduce financial burden to the system," Joshua Ofman, Amgen's senior vice president of Global Value, Access & Policy, said in a statement. "It is our hope that this collaboration with Humana, a first of its kind for Amgen, will cultivate value-based, integrated approaches to care that will focus on patients and benefit the healthcare system more broadly."
Six projects are underway as part of the collaboration. Across all six, the goal is the same – to deliver increased value to patients. In the first phase of the collaboration, researchers will target multiple serious conditions, including cardiovascular disease, osteoporosis, neurologic disorders, inflammatory diseases and cancer.
"Humana is focused on the holistic health of our members and by teaming up with Amgen we can study new ways to improve the health outcomes for our members," Laura Happe, chief pharmacy officer for Humana, said. "At the same time, we hope this research results in new tools and technology that support our provider partners who are on the journey to population health and value-based care."